Guardant Health, Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Guardant Health, Inc. (Nasdaq: GH)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A leading precision oncology company providing blood and tissue tests for cancer screening, monitoring, and treatment selection. Key products include the Guardant360 CDx (FDA-approved companion diagnostic), Guardant360 Liquid, Guardant Reveal (minimal residual disease), and the Shield blood test (FDA-approved for colorectal cancer screening). The company operates a single reporting segment and is headquartered in Palo Alto, California.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $982.0 | $739.0 | +33% |
| Net Loss | $(416.3) | $(436.4) | -4.6% |
| Operating Loss | $(437.2) | $(443.6) | -1.4% |
| Cash, Cash Equivalents, and Marketable Securities | $1.3 billion | $0.9 billion | N/A |
| Convertible Senior Notes (Net Carrying Amount) | $1.5 billion | $1.1 billion | N/A |
| Stock-Based Compensation | $166.2 | $140.4 | +18% |
Note: The filing does not provide a specific "Gross Margin" percentage, but Cost of Revenue was $349.0 million in 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 33% year-over-year, driven by a 26% increase in Oncology revenue (volume up to ~276,000 tests) and a significant expansion in Screening revenue ($79.7 million vs. $5.1 million in 2024) following the commercial launch of the Shield test.
- Expense Increases: Sales and marketing expenses rose 36% to $494.7 million due to commercial team expansion and Shield launch marketing. General and administrative expenses increased 17% to $211.4 million, largely due to higher stock-based compensation.
- Debt Restructuring: In February 2025, the company exchanged $659.3 million of 2027 Notes for $600 million of new 2031 Notes. In November 2025, it issued $402.5 million of new 2033 Notes. This resulted in a $13.7 million gain on extinguishment of debt.
- Acquisition: In December 2025, Guardant acquired MetaSight Diagnostics Ltd. for approximately $93.0 million in total consideration (including contingent consideration), adding to goodwill and intangible assets.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue investing in clinical studies, product development, and international expansion. The company anticipates continued operating losses in the near future as it scales operations. Key strategic focuses include expanding the Shield platform to lung cancer and multi-cancer detection (MCD) and increasing biopharmaceutical partnerships.
Key Risks and Contingencies:
- Profitability: The company has incurred significant losses since inception with an accumulated deficit of $3.0 billion as of December 31, 2025. There is no assurance it will achieve or maintain profitability.
- Reimbursement Uncertainty: Revenue recognition relies on estimates of variable consideration from payers. Changes in payer policies, coding, or reimbursement rates could lead to revenue reversals.
- Legal Proceedings:
- Patent Litigation: A jury verdict in November 2023 awarded TwinStrand Biosciences and the University of Washington $83.4 million in damages for patent infringement. The company is contesting this via post-trial motions and appeals; USPTO reexamination actions have rejected claims of the asserted patents.
- False Advertising: The company won a $287.0 million verdict against Natera, Inc. for false advertising in late 2024/early 2025. Natera has filed post-trial motions.
- Regulatory: The company is cooperating with a False Claims Act investigation regarding billing for Guardant360 tests.
- Regulatory Changes: Potential changes in FDA enforcement discretion regarding Laboratory Developed Tests (LDTs) could impose significant new regulatory requirements and costs.
Investor Verification Checklist
- Reimbursement Rates: Verify the stability of Medicare and commercial payer reimbursement rates for the Shield and Guardant360 tests, given the reliance on variable consideration estimates.
- Legal Reserves: Monitor the status of the $83.4 million TwinStrand liability and the $287.0 million Natera award, including the likelihood of collection or reversal on appeal.
- Cash Burn: Assess the runway provided by the $1.3 billion cash position against the current operating loss of ~$416 million annually and planned capital expenditures for international expansion.
- Debt Conversion: Review the terms of the 2031 Notes, which became convertible in Q1 2026, and the potential for dilution or cash settlement obligations.
- Shield Adoption: Track the volume growth of the Shield screening test post-FDA approval and its inclusion in payer formularies to validate the revenue trajectory.